Back to top
UDENYCA® is designed to support your patient’s treatment journey 
UDENYCA® is designed to support your patient’s treatment journey 
Febrile neutropenia (FN) is a common and potentially life-threatening complication of chemotherapy1-3
  • For patients with cancer who visit the emergency department for FN, nearly all visits end in hospitalization4
  • FN can cause treatment delays and dose reductions, leading to negative outcomes1
The impact of febrile neutropenia and guidelines for treatment
AVERAGE LENGTH OF HOSPITAL STAY DUE TO FN:
5.7-9.6 days
FOR ADULTS5,6
6.2-6.8 days
FOR ELDERLY PATIENTS7
Mortality rate in adults with cancer hospitalized for neutropenia/FN:
2.6%-7.0%
(solid tumors)4,5
7.4%
(hemotologic malignancies)4
Disease-related factors that increase the likelihood of hospitalization for neutropenia/FN include:
  • Older age
  • Presence of comorbidities
  • Advanced-stage disease
  • First-cycle chemotherapy with average relative dose intensity ≥85%3,4
FN can result in a high cost to the healthcare system
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommendation for G-CSF use during chemotherapy8
G-CSF (e.g., pegfilgrastim) primary prophylaxis may support optimal dose intensity and clinical outcomes in certain patients undergoing myelosuppressive chemotherapy.9
When FN risk is >20%, G-CSF prophylaxis*9:
When FN risk is >20%, 
G-CSF prophylaxis*9:
Significantly improved the relative dose intensity (RDI) of chemotherapy with an average difference in RDI of 8.4%9
(G-CSF-treated patients vs non-G-CSF-treated patients)
Reduced the risk of FN9
(RR: 0.54; 95% CI, 0.43–0.67)
G-CSF was shown to increase RDI and is associated with survival benefit†9
Important considerations
*
Results from a systematic review of 17 randomized trials, which included 3493 patients with solid tumors and lymphoma. G-CSF included filgrastim and pegfilgrastim.
†
Survival benefit not included in UDENYCA® prescribing information.
CI = confidence interval; G-CSF = granulocyte colony stimulating factor; RR = relative risk.
THREE ADMINISTRATION OPTIONS
Multiple administration options allow you to prescribe based on the needs of your patients. 
Explore administration options
ESTABLISHED OUTCOMES
UDENYCA® was demonstrated to be highly similar to Neulasta®, with no clinically meaningful differences.10,11
Review clinical data
INDICATION
UDENYCA® (pegfilgrastim-cbqv) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies
IMPORTANT SAFETY INFORMATION
CONTRAINDICATION: Patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products. Reactions have included anaphylaxis.